Charles River Laboratories International, Inc. (CRL) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of anima...
Charles River Laboratories International, Inc.'s revenue decreased 0.9% year over year, from $4.05B to $4.02B.
Net income decreased 750.1% over the same period, from $22.2M to $-144.3M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 139% in total.
Total debt remained relatively stable at $2.14B.
The debt-to-equity ratio stands at 0.68, indicating a moderate leverage profile.
Operating cash flow grew 0.4% to $737.6M.
Charles River Laboratories International, Inc. maintains a negative net profit margin of -3.6%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $1.01B-1.6% | $69.7M | $349.0M | $117.4M | $251.8M | $8.00B | $2.33B | $3.78B |
| Q4 FY2024 | $1.00B-0.7% | $-214.5M | $284.2M | $150.8M | $159.4M | $7.53B | $2.24B | $3.46B |
| Q1 FY2025 | $984.2M-1.8% | $25.5M | $317.7M | $74.7M | $171.7M | $7.58B | $2.51B | $3.19B |
| Q2 FY2025 | $1.03B+4.9% | $52.3M | $357.1M | $100.1M | $204.6M | $7.56B | $2.33B | $3.35B |
| Q3 FY2025 | $1.00B-2.6% | $54.4M | $338.8M | $133.8M | $213.8M | $7.51B | $2.19B | $3.41B |
| Q4 FY2025 | $994.2M-1.1% | $-276.6M | $309.7M | $189.2M | $147.5M | $7.14B | $2.14B | $3.16B |
| Q1 FY2026 | $995.8M+0.2% | $-14.8M | $182.6M | $119.9M | $41.1M | $7.73B | $3.06B | $2.99B |
| Q2 FY2026 | $1.00B+0.8% | $-1.5M | $278.8M | $119.9M | $179.7M | $7.53B | $3.03B | $2.89B |
Balance Sheet Summary (Q2 FY2026)
Charles River Laboratories International, Inc. (CRL) Financial Statements & Revenue History
Charles River Laboratories International, Inc. (CRL) is a US-listed stock operating in the Healthcare sector, specifically the Services-Commercial Physical & Biological Research industry trading at $300.15 with a market capitalization of $14. This page provides 42 historical financial statements for Charles River Laboratories International, Inc., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Charles River Laboratories International, Inc. reported revenue of $4.0 billion, a 0.9% decline from the prior year. The net profit margin of -3.6% indicates the company is currently unprofitable. The debt-to-equity ratio of 0.68 reflects moderate leverage.
CRL Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Charles River Laboratories International, Inc.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether CRL is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track CRL's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Charles River Laboratories International, Inc. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of CRL's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use CRL Financial Data
Investors use Charles River Laboratories International, Inc.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare CRL's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how CRL's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View CRL's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Charles River Laboratories International, Inc.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.CRL trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.